Dental manifestations in adult hypophosphatasia and their correlation with biomarkers
- PMID: 36101824
- PMCID: PMC9458606
- DOI: 10.1002/jmd2.12307
Dental manifestations in adult hypophosphatasia and their correlation with biomarkers
Abstract
Hypophosphatasia (HPP) is a genetic condition with broad clinical manifestations caused by alkaline phosphatase (ALP) deficiency. Adults with HPP exhibit a wide spectrum of signs and symptoms. Dental manifestations including premature tooth loss are common. Much of the published literature reporting dental manifestations consists of case reports and series of symptomatic patients, likely biased towards more severe dental manifestations. The objective of this study was to systematically explore the dental manifestations among adults with HPP by conducting a comprehensive dental evaluation. To minimize bias, the study explored dental manifestations in an unselected cohort of adults with HPP. Participants were identified searching electronic health record (EHR) data from a rural health system to discover adults with persistent ALP deficiency. Heterozygotes with pathogenic (P), likely pathogenic (LP), or uncertain variants (VUS) in ALPL and at least one elevated ALP substrate were defined as adults with HPP and underwent genetic, dental, oral radiographic, and biomarker evaluation. Twenty-seven participants completed the study. Premature tooth loss was present in 63% (17/27); 19% (5/27) were missing eight or more teeth. Statistically significant associations were found between premature permanent tooth loss and HPP biomarkers ALP (p = 0.049) and bone-specific ALP (p = 0.006). Serum ALP (ρ = -0.43, p = 0.037) and bone-specific ALP (ρ = -0.57, p = 0.004) were negatively correlated with number of teeth lost prematurely. As noted with tooth loss, periodontal breakdown was associated with bone-specific ALP. An inverse association between periodontal breakdown and bone-specific ALP was observed (p = 0.014). These findings suggest a role for ALP in maintenance of dentition.
Keywords: alkaline phosphatase; asfotase alfa; dental; enzyme replacement therapy; hypophosphatasia; periodontal breakdown; tooth loss.
© 2022 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.
Conflict of interest statement
Robert D. Steiner reports equity interest in and consulting fees from Acer Therapeutics and PTC Therapeutics, research funded by Alexion and the Smith Lemli Opitz Syndrome Foundation. In the past 5 years, travel support from Pfizer to review clinical trial results. In the past 5 years consulting fees from Aeglea, Alexion, Best Doctors, Biomarin, E‐Scape Bio, Health Advances, Leadiant, Precision for Value, Retrophin/Travere, and Honoraria from Medscape/WebMD and The France Foundation. Robert Steiner is also an employee of PreventionGenetics. No additional potential conflicts of interest exist on the part of Dr. Steiner. Priya Sinha, Rachel Gabor, Rachael Haupt‐Harrington, and Leila Deering declare no real or potential conflict of interest.
Figures
References
-
- Whyte MP. Hypophosphatasia. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw Hill; 2019:1.
-
- Whyte MP. Hypophosphatasia. In: Thakker RV, Whyte MP, Eisman J, Igarashi T, eds. Genetics of Bone Biology and Skeletal Disease. Academic Press; 2013:337‐360.
-
- Mornet E, Nunes ME. Hypophosphatasia. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. University of Washington; 2007.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
